8-K: Shuttle Pharmaceuticals Appoints Timothy Lorber as Chief Financial Officer, Michael Vander Hoek Transitions to VP of Regulatory

Shuttle Pharmaceuticals has appointed Timothy Lorber as its new Chief Financial Officer, while current CFO Michael Vander Hoek will transition to a full-time Vice President of Regulatory role.

Summary

• Shuttle Pharmaceuticals has hired Timothy J. Lorber as their new Chief Financial Officer (CFO).
• Mr. Lorber will initially serve as a part-time CFO until September 9, 2024, and then transition to a full-time role starting September 10, 2024.
• He will receive an annual base salary of $227,000, a grant of 227,635 restricted stock units (RSUs) vesting over three years, and is eligible for a milestone-based bonus of up to $72,000.
• The current CFO, Michael Vander Hoek, will transition to a full-time Vice President of Regulatory role on September 10, 2024.
• Mr. Lorber has over 40 years of finance experience, including 15 years at Legg Mason, and has experience with valuations, M&A transactions, and SEC reporting.
• Mr. Vander Hoek has served as both CFO and VP of Regulatory for the past four years and will now focus solely on regulatory matters.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of an experienced CFO and the strategic realignment of the current CFO to a critical regulatory role. The company is clearly positioning itself for growth and clinical trial advancement.

Positives

• The appointment of Timothy Lorber brings a seasoned financial professional with over 40 years of experience, including significant experience with valuations, M&A transactions, and SEC reporting.
• Mr. Lorber's experience includes 15 years at Legg Mason, a large global asset management firm.
• The transition allows Michael Vander Hoek to focus entirely on the critical regulatory aspects of the business, particularly as the company ramps up its clinical activities.
• The company is providing a competitive compensation package to Mr. Lorber, including a base salary, stock options, and a potential bonus.

Risks

• The transition of the CFO role could create a temporary disruption in financial management.
• The company's success is dependent on the successful execution of its clinical trials and regulatory approvals.
• The company's future performance is subject to various risks, including those detailed in their SEC filings.

Future Outlook

The company plans to advance its mission to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of Radiation Therapy while limiting the late effects of radiation in cancer treatment. They are also planning the initiation of a multi-center Phase 2 clinical trial.

Management Comments

• Anatoly Dritschilo, M.D., CEO of Shuttle Pharma, stated that they are extremely excited to welcome Tim Lorber to the executive team.
• Dr. Dritschilo believes Mr. Lorber's deep experience will serve the company well as they advance their mission.
• Dr. Dritschilo also thanked Michael Vander Hoek for his hard work as CFO and looks forward to his contributions as they ramp up clinical activities.

Industry Context

This announcement reflects a strategic move by Shuttle Pharmaceuticals to strengthen its financial leadership as it progresses through clinical trials. The appointment of a seasoned financial executive like Mr. Lorber is common for companies in the biotechnology sector as they move towards commercialization. The transition of the current CFO to a full-time regulatory role also highlights the increasing importance of regulatory compliance in the pharmaceutical industry.

Comparison to Industry Standards

• The appointment of a CFO with extensive experience, including time at a major financial firm like Legg Mason, is consistent with industry standards for biotech companies preparing for growth and potential commercialization.
• The compensation package, including a base salary, stock options, and a potential bonus, is also in line with industry norms for executive-level positions in similar-sized pharmaceutical companies.
• The transition of the current CFO to a full-time regulatory role is a common practice in the pharmaceutical industry, where regulatory compliance is a critical function.
• Comparable companies in the biotech space, such as those focused on oncology therapeutics, often have similar executive structures with dedicated financial and regulatory leadership.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced CFO positively, potentially increasing investor confidence.
• Employees may experience changes in leadership and reporting structures.
• The transition of the CFO to a full-time regulatory role may improve the company's ability to navigate regulatory requirements.
• The company's focus on clinical trials and regulatory compliance may impact its relationships with research organizations and regulatory bodies.

Next Steps

• Timothy Lorber will begin his part-time role as CFO and transition to full-time on September 10, 2024.
• Michael Vander Hoek will transition to his full-time role as Vice President of Regulatory on September 10, 2024.
• The company will continue to advance its clinical programs, including the planned initiation of a multi-center Phase 2 clinical trial.

Key Dates

Keywords

Chief Financial Officer, CFO, Timothy Lorber, Michael Vander Hoek, Regulatory, Shuttle Pharmaceuticals, Executive Appointment, Finance, Clinical Trials, SEC Filings